{"nctId":"NCT00265343","briefTitle":"6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)","startDateStruct":{"date":"2005-12"},"conditions":["Schizophrenia"],"count":306,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: asenapine"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: olanzapine"]}],"interventions":[{"name":"asenapine","otherNames":[]},{"name":"olanzapine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Continue to meet all demographic and procedural\n\ninclusion criteria of the 25543 trial (NCT 00212836; P05817) to enter into\n\nthis extension trial.\n\n* Have demonstrated an acceptable\n\ndegree of compliance and completed the 25543\n\ntrial, and would benefit from continued treatment\n\naccording to the investigator.\n\nExclusion Criteria:\n\n* Have an uncontrolled, unstable clinically significant\n\nmedical condition.\n\n* Have been judged to be medically\n\nnoncompliant in the management of their disease.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Long-term Change in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale","description":"Decrease from baseline in the NSA scores indicates improvement of efficacy. Range NSA total score is 16 \\[best\\]-96 \\[worst\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.9","spread":"0.98"},{"groupId":"OG001","value":"-15.4","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life Measured by Quality of Life Scale (QLS)","description":"Increase from baseline in the QLS scores indicates improvement of efficacy. Range QLS total score is 0 \\[worst\\]-126 \\[best\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","spread":"1.64"},{"groupId":"OG001","value":"16.4","spread":"1.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":134},"commonTop":["Headache","Weight increased","Influenza","Schizophrenia"]}}}